Mori, Keiichiro http://orcid.org/0000-0002-6147-6569
Schuettfort, Victor M.
Egawa, Shin
Compérat, Eva
Shariat, Shahrokh F.
Funding for this research was provided by:
Medical University of Vienna
Article History
Received: 17 March 2022
Accepted: 17 March 2022
First Online: 12 April 2022
Disclosures
: Shahrokh Shariat owns or co-owns the following patents: Methods to determine prognosis after therapy for prostate cancer. Granted 2002-09-06. Methods to determine prognosis after therapy for bladder cancer. Granted 2003-06-19. Prognostic methods for patients with prostatic disease. Granted 2004-08-05. Soluble Fas: urinary marker for the detection of bladder transitional cell carcinoma. Granted 2010-07-20. He has a consulting or advisory role for the following: Astellas, Astra Zeneca, Bayer, BMS, Cepheid, Ferring, Ipsen, Jansen, Lilly, MSD, Olympus, Pfizer, Pierre Fabre, Roche, Sanochemia, Sanofi, Takeda, Urogen, and Wolff.